Monopar Therapeutics (MNPR) Profit After Tax (2017 - 2025)

Monopar Therapeutics (MNPR) has 9 years of Profit After Tax data on file, last reported at -$3.5 million in Q3 2025.

• For the quarter ending Q3 2025, Profit After Tax fell 168.61% year-over-year to -$3.5 million; the trailing twelve-month figure through Sep 2025 stood at -$9.9 million (down 49.39% YoY), and the FY2025 full-year result was -$13.7 million, up 11.45% from the prior year.
• Profit After Tax declined to -$3.5 million in Q3 2025, from -$2.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$57.0 in Q2 2021 to a low of -$3.5 million in Q3 2025.
• A 5-year average of -$2.2 million and a median of -$2.4 million in 2023 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax soared 100.0% in 2021 and slumped 4847147.37% in 2022, its largest moves.
• Tracing MNPR's Profit After Tax over 5 years: stood at -$2.7 million in 2021, then retreated by 7.68% to -$2.9 million in 2022, then jumped by 32.15% to -$2.0 million in 2023, then soared by 33.35% to -$1.3 million in 2024, then plunged by 168.61% to -$3.5 million in 2025.
• Business Quant data shows MNPR's Profit After Tax at -$3.5 million in Q3 2025, -$2.5 million in Q2 2025, and -$2.6 million in Q1 2025.